Dichloroisoprenaline
Dichloroisoprenaline, also known as dichloroisoproterenol, was the first beta blocker ever to be developed. It is non-selective for the β1-adrenergic and β2-adrenergic receptors. DCI has low potency and acts as a partial agonist/antagonist at these receptors.
Although DCI was of no clinical value itself, further developments from DCI eventually led to the development of the clinical candidate pronethalol and subsequently propranolol.
Dichloroisoprenaline is a racemic mixture of enantiomers.
